...
首页> 外文期刊>Expert Review of Molecular Diagnostics >Th2 cells as targets for therapeutic intervention in allergic bronchial asthma.
【24h】

Th2 cells as targets for therapeutic intervention in allergic bronchial asthma.

机译:Th2细胞作为过敏性支气管哮喘的治疗干预靶标。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Th2 cells play a central role in the pathogenesis of allergic bronchial asthma, since each of their characteristic cytokines such as IL-4, IL-5, IL-9 and IL-13 contributes to hallmarks of this disease, including airway eosinophilia, increased mucus production, production of allergen-specific IgE and development of airway hyper-responsiveness. Therefore, these cells are predisposed as target cells for therapeutic intervention. Experimental approaches targeted Th2-type effector cytokines, Th2-cell recruitment and Th2-cell development. Another strategy uses the immunomodulatory potential of tolerance-inducing cytokines such as IL-10 or of cytokines such as IL-12, IL-18 and IFN-gamma that are able to induce a counterbalancing Th1 immune response.
机译:Th2细胞在过敏性支气管哮喘的发病机理中起着关键作用,因为它们的每种特征性细胞因子(例如IL-4,IL-5,IL-9和IL-13)均是该疾病的标志,包括气道嗜酸性粒细胞增多,粘液增多过敏原特异性IgE的生产,生产以及气道高反应性的发展。因此,这些细胞易于作为治疗干预的靶细胞。实验方法针对Th2型效应细胞因子,Th2细胞募集和Th2细胞发育。另一种策略使用诱导耐受的细胞因子(例如IL-10)或细胞因子(例如IL-12,IL-18和IFN-γ)的免疫调节潜能,它们能够诱导平衡的Th1免疫应答。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号